Bone morphogenetic protein-2 (BMP-2) in the treatment of pyogenic vertebral osteomyelitis.

Study Design: Retrospective case series.

Objective: To present results of recombinant human bone morphogenetic protein-2 (rhBMP-2) use in medically nonresponsive pyogenic vertebral osteomyelitis (PVO), treated by anterior/posterior debridement and instrumented fusion in the cervical, thoracic, and lumbosacral spine.

Summary Of Background Data: Surgical options for PVO vary, as do their outcomes, and can be complicated by recurrence, pseudarthrosis, and death.